GlassScriptPhysician profile
Mary E Casbarro
NPI 1346793981
$3,611.51
in general payments reported to CMS, 2019-2025
25 companies · $809 in 2025
The $809 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $703 · 2023: $836 · 2024: $994 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,554 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,553.62 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.42 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $419.24 | 2021-2025 | |
| Astellas Pharma US INC | $346.70 | 2022-2025 | Veozah |
| Exeltis, USA INC. | $303.43 | 2023-2024 | Slynd |
| Optumhealth Care Solutions, LLC | $260.06 | 2023-2025 | Vivify Health Care Team Portal 001, Eitan Medical, Vivify Health Care Team Portal |
| Agile Therapeutics, INC. | $188.41 | 2021-2024 | Twirla |
| Exact Sciences Corporation | $118.55 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $112.12 | 2022-2025 | Nexplanon |
| Biogen, INC. | $110.35 | 2024-2025 | Zurzuvae |
| Millicent US INC | $84.77 | 2024-2025 | Intrarosa, Femlyv |
| Merck Sharp & Dohme LLC | $76.91 | 2022-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $67.54 | 2021-2022 | |
| Coopersurgical, INC. | $62.12 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $55.70 | 2023-2024 | |
| Gynesonics, INC. | $34.29 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $32.58 | 2023-2025 | Accrufer |
| Pfizer INC. | $29.26 | 2025 | |
| Medtronic, INC. | $21.47 | 2023 | |
| Myovant Sciences INC. | $18.68 | 2021 | |
| Aspira Women'S Health INC | $17.50 | 2021 | |
| Radius Health, INC. | $17.42 | 2025 | Tymlos |
| Avion Pharmaceuticals | $16.34 | 2022 | |
| Ibsa Pharma INC. | $16.25 | 2023 | Tirosint, Licart |
| Hologic Sales and Service, LLC | $14.16 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Therapeuticsmd, INC. | $13.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Casbarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.